Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial
The monthly dosing schedule demonstrated low rates of cytokine release syndrome and fatal infections.
Marissa Russo
Sep 3, 2026 9:20am
Context ends bispecific trial to extend runway deeper into 2027
Aug 6, 2026 5:55am
Vertex’s latest autoimmune TCE play involves $28M to AbCellera
Jul 29, 2026 8:20am
Roche drops lupus TCE, retains autoimmune cell therapy interest
Jul 23, 2026 4:51am
Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE
Jun 30, 2026 8:00am
Cullinan's new data makes clearest case yet for autoimmune TCEs
Jun 6, 2026 5:15am
